Key Limitations and Diagnostic Gaps in PAT Technology Home Sleep Apnea Testing

The article examines the PAT Technology HSAT, a home-based tool for sleep apnea testing, which uses Peripheral Arterial Tonometry (PAT) rather than direct respiratory monitoring to detect sleep-disordered breathing. While convenient, PAT Technology HSAT’s indirect approach—tracking oxygen levels, heart rate, and autonomic responses—presents limitations, particularly in detecting mild cases and central sleep apnea (CSA). Studies indicate PAT Technology HSAT’s lower correlation to polysomnography (PSG), the gold standard in sleep apnea testing, with higher rates of false positives and false negatives, especially in patients with atrial fibrillation (AFib) or borderline/mild obstructive sleep apnea (OSA). Alternatives like the Wesper device, which uses direct respiratory measurements, offer more reliable diagnoses, highlighting the importance of device choice for accurate detection and effective treatment planning in sleep apnea patients.

Dr. Chelsie Rohrscheib, PhD 
Head Sleep Expert & Neuroscientist 
October 31, 2024

The PAT Technology HSAT is a home sleep apnea testing tool that utilizes Peripheral Arterial Tonometry (PAT) to assess oxygen levels, heart rate, and autonomic nervous system responses to detect sleep apnea. Unlike other devices that measure respiratory signals directly, PAT Technology HSAT interprets fluctuations in vascular tone as an indirect indicator of sleep-disordered breathing events.

Furthermore, PAT Technology HSAT struggles with accurately detecting CSA due to its reliance on indirect autonomic responses. In contrast, more sophisticated devices like Wesper utilize multiple biosensors and direct respiratory measurements, allowing for better identification of CSA with minimal misclassification. This shortfall makes PAT Technology HSAT a less suitable choice for individuals with mixed or central sleep apnea, potentially leading to underdiagnoses in patients who require targeted treatment for CSA.

PAT Technology HSAT's indirect detection mechanism introduces a greater likelihood of false positives and false negatives, especially in patients with borderline/mild OSA or conditions like atrial fibrillation (AFib), which disrupt regular heart rhythms. Research indicates that in AFib patients, PAT signals can become unreliable, leading to the exclusion of affected signals and resulting in misclassifications and missing data. 

While PAT Technology HSAT offers a convenient alternative to polysomnography (PSG), its limitations are significant. Compared to PSG or devices like Wesper, which reports a 95% correlation with PSG results, PAT Technology HSAT's correlation rates range from 85% to 90% for moderate-to-severe obstructive sleep apnea (OSA), with notably less accuracy for mild cases (Table 1). This inconsistency can lead to inaccurate classifications, particularly for milder or transient apneic events. 

For example, A large-scale meta-analysis by Iftikhar et al., (2022), which evaluated 17 studies with 1,318 participants undergoing simultaneous PSG and PAT Technology testing, indicated an overall correlation of 90% with PSG. However, accuracy significantly depended on patient severity. For instance, at an Apnea-Hypopnea Index (AHI) threshold of ≥5, the false positive rate was 5.9% and the false negative rate was 56.5%. At an AHI threshold of ≥15, the false positive rate rose to 7.8%, with a false negative rate of 27.6%. At an AHI threshold of ≥30, the false positive rate jumped to 25.9%, and the false negative rate was 12.9%. 

Additionally, a 2020 study by Jen et al., presents concerning limitations regarding the efficacy of the PAT Technology HSAT for diagnosing sleep apnea, particularly in patients with AFib. Although the study claims that PAT Technology HSAT offers comparable accuracy to polysomnography (PSG), its correlation rates and overall diagnostic reliability raise significant doubts. 

The reported correlation of PAT Technology HSAT with PSG outcomes suggests moderate agreement at 85%, with a high false positive (13%) and extremely high false negative (20%) rate. This is inadequate when considering the critical implications of misdiagnosis in patients with AFib. Moreover, the unique challenges presented by AFib complicate the detection of sleep-disordered breathing. The device's reliance on autonomic signals can result in high rates of false positives and negatives, particularly since AFib patients may not exhibit typical sleep apnea symptoms. This unreliability is particularly problematic, as misclassification can prevent appropriate treatment for a condition that is already prevalent among this demographic. Therefore, while PAT Technology HSAT may serve as a potential alternative for sleep apnea diagnosis, its shortcomings, particularly in the context of AFib patients, suggest that it may not be a trustworthy option for accurate diagnosis.

A 2019 multi-center study evaluated CSA in adult patients using PAT Technology HSAT. The correlation of CSA detection betweenPAT Technology HSAT and PSG was notably low. The f indings indicated that the overall agreement for CSA detection was only about 66.5%, with a false positive rate of 50% and false negative rate of 17%. These statistics suggest that PAT Technology HSAT is not highly effective in accurately diagnosing CSA when compared to PSG. Other similar studies have shown poor CSA detection in patients with AFib. 

In conclusion, while PAT Technology HSAT presents a convenient home testing option, its limitations in accuracy, particularly for mild cases and central apnea detection, warrant caution. More reliable alternatives, such as Wesper, are necessary to ensure precise diagnosis and treatment of sleep-disordered breathing. 

Table 1: Accuracy of PAT Technology HSAT compared to PSG

1. What is PAT Technology HSAT?
PAT Technology HSAT is a home sleep apnea testing tool that uses Peripheral Arterial Tonometry (PAT) to assess vascular tone as an indirect measure of sleep-disordered breathing. Unlike traditional methods, it doesn’t directly measure respiratory signals, but instead detects changes in heart rate and autonomic nervous system responses during sleep.

2. How accurate is PAT Technology HSAT?
While PAT Technology HSAT offers a convenient home testing option, its accuracy is lower compared to polysomnography (PSG) and other devices like Wesper. Studies show that its correlation with PSG results ranges from 85% to 90% for moderate-to-severe obstructive sleep apnea (OSA), but it has a higher rate of false positives and false negatives, particularly for mild cases.

3. Does PAT Technology HSAT work for central sleep apnea (CSA)?
No, PAT Technology HSAT is not very effective at detecting central sleep apnea. It has shown a low correlation for CSA detection, with studies reporting only about 66.5% agreement with PSG. The device’s reliance on autonomic signals makes it less reliable for CSA diagnosis, especially in patients with heart arrhythmias like atrial fibrillation (AFib).

4. Are there any limitations with using PAT Technology HSAT for patients with AFib?
Yes, PAT Technology HSAT is less reliable in patients with AFib. The device's reliance on autonomic signals can lead to high false positive and false negative rates in this group, making it difficult to accurately diagnose sleep apnea in individuals with heart arrhythmias. This may lead to misdiagnoses or missed opportunities for treatment.

5. Is PAT Technology HSAT suitable for mild cases of sleep apnea?
PAT Technology HSAT is less accurate for diagnosing mild or borderline obstructive sleep apnea. Research indicates that its ability to detect milder apneic events is inconsistent, with a higher likelihood of missed diagnoses compared to more sophisticated systems like PSG or Wesper.

6. Should I rely on PAT Technology HSAT for sleep apnea diagnosis?
While PAT Technology HSAT provides a convenient alternative for sleep apnea testing at home, its limitations in accuracy—especially for mild OSA and central sleep apnea—mean that it may not be the best option for everyone. For more accurate and reliable results, especially in complex cases, alternatives like Wesper or a full polysomnography (PSG) test are recommended.

1. Yalamanchali S, Farajian V, Hamilton C, Pott TR, Samuelson CG, Friedman M. Diagnosis of Obstructive Sleep Apnea by Peripheral Arterial Tonometry: Meta-analysis. JAMA Otolaryngol Head Neck Surg. 2013;139(12):1343–1350. doi:10.1001/jamaoto.2013.5338 
2. Iftikhar IH, Finch CE, Shah AS, Augunstein CA, Ioachimescu OC. A meta-analysis of diagnostic test performance of peripheral arterial tonometry studies. J Clin Sleep Med. 2022 Apr 1;18(4):1093-1102. doi: 10.5664/jcsm.9808. PMID: 34879903; PMCID: PMC8974372. 
3. Jen R, Orr JE, Li Y, DeYoung P, Smales E, Malhotra A, Owens RL. Accuracy of PAT Technology HSAT for the Diagnosis of Obstructive Sleep Apnea in Patients with Chronic Obstructive Pulmonary Disease. COPD. 2020 Feb;17(1):34-39. 
4. Pillar G, Berall M, Berry R, Etzioni T, Shrater N, Hwang D, Ibrahim M, Litman E, Manthena P, Koren-Morag N, Rama A, Schnall RP, Sheffy K, Spiegel R, Tauman R, Penzel T. Detecting central sleep apnea in adult patients using PAT Technology HSAT-a multicenter validation study. Sleep Breath. 2020 Mar;24(1):387-398. doi: 10.1007/s11325-019-01904-5. Epub 2019 Aug 11. PMID: 31402439; PMCID: PMC7127995. 
5. Tauman R, Berall M, Berry R, Etzioni T, Shrater N, Hwang D, Marai I, Manthena P, Rama A, Spiegel R, Penzel T, Koren Morag N, Pillar G. Watch-PAT is Useful in the Diagnosis of Sleep Apnea in Patients with Atrial Fibrillation. Nat Sci Sleep. 2020 Dec 3;12:1115-1121. doi: 10.2147/ NSS.S278752. PMID: 33299372; PMCID: PMC7721305.